Avid Bioservices Inc. (CDMO)
NASDAQ: CDMO
· Real-Time Price · USD
12.49
0.00 (0.00%)
At close: Feb 04, 2025, 3:59 PM
0.00% (1D)
| Bid | n/a |
| Market Cap | 798.9M |
| Revenue (ttm) | 142.36M |
| Net Income (ttm) | -144.15M |
| EPS (ttm) | -2.41 |
| PE Ratio (ttm) | -5.182572614107884 |
| Forward PE | -113.55 |
| Analyst | Hold |
| Ask | n/a |
| Volume | 0 |
| Avg. Volume (20D) | 1,584,407 |
| Open | 12.49 |
| Previous Close | 12.49 |
| Day's Range | 12.49 - 12.49 |
| 52-Week Range | 5.90 - 12.51 |
| Beta | 1.41 |
About CDMO
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk p...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 4, 1994
Employees 371
Stock Exchange NASDAQ
Ticker Symbol CDMO
Website https://www.avidbio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CDMO stock is "Hold." The 12-month stock price forecast is $12.25, which is a decrease of -1.92% from the latest price.
Stock ForecastsNext Earnings Release
Avid Bioservices Inc. is scheduled to release its earnings on May 2, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
Avid Biosciences shares are trading higher after t...
Unlock content with
Pro Subscription
7 months ago
Avid Bioservices shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results. Also, RBC Capital maintained an Outperform rating on the stock and raised its price target from $8 to $12.
